The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
Open accessAbstract
Background Rheumatoid arthritis (RA) is a common inflammatory autoimmune disease that places a substantial burden on health care systems. Although there is currently no cure for RA, improved understanding of RA disease pathogenesis in recent years has led to the development of new biologic treatments designed to target specific elements of the RA inflammatory response. Objective To provide individuals responsible for decision making within managed care environments, including pharmacists, physicians, and other healthcare professionals, with a review of biologic therapies currently used for the treatment of RA. Investigational treatments for RA are also discussed. Methods A narrative review of the peer-reviewed, published literature on biologic therapies in the treatment of RA was performed. Results The treatment of RA is aimed at achieving the lowest possible disease activity and ideally remission. Biologic agents that target specific components of the immune response are highly effective in reducing RA symptoms, slowing the rate of disease progression, and improving physical function and quality of life measures in patients with moderate to severe RA. Dosing schedules and routes of administration vary depending on the biologic used, and these factors influence the cost of therapy and patient and physician preference. Conclusion The treatment of RA has been transformed in the last decade with the introduction of several targeted biologic agents. Although biologic agents are more costly in the short term than conventional disease-modifying antirheumatic drugs, drug-specific costs may be offset by significant improvements in RA symptoms, slowed disease progression, and improved physical function and quality of life for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23176 · Cited by 5,499
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Cytokines in the pathogenesis of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2094 · Cited by 2,529
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I
Helmick, C. G., Felson, D. T., Lawrence, R. C., Gabriel, S., Hirsch, R., Kwoh, C. K., Liang, M. H., Kremers, H. M., Mayes, M. D., Merkel, P. A., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23177 · Cited by 2,058
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,640
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Rheumatoid Arthritis: Pathophysiology and Implications for Therapy
Epstein, F. H., & Harris, E. D. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221805 · Cited by 1,551
Goekoop‐Ruiterman, Y. P. M., De Vries‐Bouwstra, J. K., Allaart, C. F., Van Zeben, D., Kerstens, P. J. S. M., Hazes, J. M. W., Zwinderman, A. H., Ronday, H. K., Han, K. H., Westedt, M. L., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21405 · Cited by 1,460
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Self-citationSt. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Möttönen, T., Hannonen, P., Leirisalo-Repo, M., Nissilä, M., Kautiainen, H., Korpela, M., Laasonen, L., Julkunen, H., Luukkainen, R., Vuori, K., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08513-4 · Cited by 865
Aletaha, D., & Smolen, J. S. (2005) · PubMed · Cited by 843
Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., & Freundlich, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61000-4 · Cited by 821
Nell, V. P. K. (2004) · Rheumatology · doi:10.1093/rheumatology/keh199 · Cited by 818
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Landewé, R. B. M., Boers, M., Verhoeven, A. C., Westhovens, R., van de Laar, M. A. F. J., Markusse, H. M., van Denderen, J. C., Westedt, M. L., Peeters, A. J., Dijkmans, B. A. C., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10083 · Cited by 612
Keystone, E., Heijde, D. V. D., Mason, D., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23964 · Cited by 576
Cohen, S. B., Dore, R. K., Lane, N. E., Ory, P. A., Peterfy, C. G., Sharp, J. T., van der Heijde, D., Zhou, L., Tsuji, W., Newmark, R., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23417 · Cited by 576
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., Pazdur, J., Bae, S.-C., Palmer, W., Zrubek, J., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099010 · Cited by 541
Saag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B., Kohler, J. A., & Furst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540
Schiff, M., Keiserman, M., Codding, C., Songcharoen, S., Berman, A., Nayiager, S., Saldate, C., Li, T., Aranda, R., Becker, J.-C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080002 · Cited by 539
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., & Dijkmans, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21671 · Cited by 471
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., & Tugwell, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007848.pub2 · Cited by 470
Self-citationEpidemiology and burden of illness of rheumatoid arthritis
Kvien, T. K. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422001-00002 · Cited by 435
Askling, J., Fored, C. M., Baecklund, E., Brandt, L., Backlin, C., Ekbom, A., Sundström, C., Bertilsson, L., Cöster, L., Geborek, P., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033241 · Cited by 417
Chen, Y.-F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., & Burls, A. (2006) · Health Technology Assessment · doi:10.3310/hta10420 · Cited by 406
Hyrich, K. L., Lunt, M., Watson, K. D., Symmons, D. P. M., Silman, A. J., & British Society for Rheumatology Biologics Register (2007) · Arthritis & Rheumatism · doi:10.1002/art.22331 · Cited by 401
Emery, P., Fleischmann, R. M., Moreland, L. W., Hsia, E. C., Strusberg, I., Durez, P., Nash, P., Amante, E. J. B., Churchill, M., Park, W., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24638 · Cited by 398
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398
Self-citation[Etanercept for therapy of rheumatoid arthritis].
Miyasaka, N. (2005) · PubMed · Cited by 367
The widening mortality gap between rheumatoid arthritis patients and the general population
Gonzalez, A., Maradit Kremers, H., Crowson, C. S., Nicola, P. J., Davis, J. M., Therneau, T. M., Roger, V. L., & Gabriel, S. E. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22979 · Cited by 357
Wolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22579 · Cited by 348
Emery, P., Deodhar, A., Rigby, W. F., Isaacs, J. D., Combe, B., Racewicz, A. J., Latinis, K., Abud-Mendoza, C., Szczepański, L. J., Roschmann, R. A., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.119933 · Cited by 348
Fleischmann, R., Vencovsky, J., van Vollenhoven, R. F., Borenstein, D., Box, J., Coteur, G., Goel, N., Brezinschek, H.-P., Innes, A., & Strand, V (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099291 · Cited by 338
Askling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062760 · Cited by 334
Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., & Silman, A. J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22808 · Cited by 307
Schneeweiss, S., Setoguchi, S., Weinblatt, M. E., Katz, J. N., Avorn, J., Sax, P. E., Levin, R., & Solomon, D. H. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22600 · Cited by 302
Weinblatt, M., Schiff, M., Goldman, A., Kremer, J., Luggen, M., Li, T., Chen, D., & Becker, J.-C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055111 · Cited by 300
Extra-articular manifestations and complications of rheumatoid arthritis
Young, A., & Koduri, G. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.05.007 · Cited by 299
Michaud, K., Messer, J., Choi, H. K., & Wolfe, F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11439 · Cited by 271
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Self-citationTumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis
Setoguchi, S., Solomon, D. H., Weinblatt, M. E., Katz, J. N., Avorn, J., Glynn, R. J., Cook, E. F., Carney, G., & Schneeweiss, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22056 · Cited by 240
Work disability in rheumatoid arthritis 10 years after the diagnosis.
Sokka, T., Kautiainen, H., Möttönen, T. T., & Hannonen, P. (1999) · PubMed · Cited by 216
Generic quality-of-life assessment in rheumatoid arthritis.
Tugwell, P., Idzerda, L., & Wells, G. A. (2007) · PubMed · Cited by 214
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Tanjong Ghogomu, E., & Tugwell, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007848 · Cited by 169
Self-citationSchoels, M., Wong, J., Scott, D. L., Zink, A., Richards, P., Landewé, R., Smolen, J. S., & Aletaha, D. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126714 · Cited by 165
Second-Line Drug Therapy for Rheumatoid Arthritis
Wood, A. J. J., Cash, J. M., & Klippel, J. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301908 · Cited by 160
Pincus, T., Swearingen, C. J., Bergman, M. J., Colglazier, C. L., Kaell, A. T., Kunath, A. M., Siegel, E. L., & Yazıcı, Y. (2010) · Arthritis Care & Research · doi:10.1002/acr.20066 · Cited by 146
Patient preferences for treatment of rheumatoid arthritis
Fraenkel, L., Bogardus, S. T., Concato, J., Felson, D. T., & Wittink, D. R. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.019422 · Cited by 113
Fleischmann, R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24906 · Cited by 112
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
Fleischmann, R., Stern, R., & Iqbal, I. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1333 · Cited by 99
Yazıcı, Y., Shi, N., & John, A. K. (2008) · PubMed · Cited by 96
Curtis, J. R., Xi, J., Patkar, N. M., Xie, A., Saag, K. G., & Martin, C. K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23050 · Cited by 93
Self-citationShergy, W. J., Isern, R. A., Cooley, D. A., Harshbarger, J. L., Huffstutter, J. E., Hughes, G. M., Spencer-Smith, E. A., Goldman, A. L., Roth, S. H., Toder, J. S., et al. (2002) · PubMed · Cited by 71
Edwards, C. J., Arden, N., Fisher, D., Saperia, J., Reading, I., van Staa, T. P., & Cooper, C. C. (2005) · Lara D. Veeken · doi:10.1093/rheumatology/kei024 · Cited by 70
Zintzaras, E., Dahabreh, I. J., Giannouli, S., Voulgarelis, M., & Moutsopoulos, H. Μ. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.007 · Cited by 61
Kielhorn, A., Porter, D. R., Diamantopoulos, A., & Lewis, G. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802321683 · Cited by 56
Cruyssen, B. V., Looy, S. V., Wyns, B., Westhovens, R., Durez, P., den Bosch, F. E. V., Mielants, H., Clerck, L. S. D., Peretz, A., Malaise, M., et al. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2001 · Cited by 55
DeWitt, E. M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.1.57 · Cited by 43
Curtis, J. R., Chen, L., Harrold, L. R., Narongroeknawin, P., Reed, G. W., & Solomon, D. H. (2009) · Arthritis Care & Research · doi:10.1002/acr.20020 · Cited by 38
Self-citationAt the horizon of innovative therapy in rheumatology: new biologic agents
Finckh, A., & Gabay, C. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282fa13b4 · Cited by 37
Yuan, Y., Trivedi, D., Maclean, R., & Rosenblatt, L. C. (2009) · Journal of Medical Economics · doi:10.3111/13696990903508021 · Cited by 25
Abatacept in the treatment of rheumatoid arthritis
Todd, D. J., Costenbader, K. H., & Weinblatt, M. E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01289.x · Cited by 24
Cited by
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Rheumatoid Arthritis: A Brief Overview of the Treatment
Bullock, J., Rizvi, S. A. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., & Ahmed, J. (2018) · Medical Principles and Practice · doi:10.1159/000493390 · Cited by 776
Methotrexate an Old Drug with New Tricks
Bedoui, Y., Guillot, X., Sélambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M. C., Ralandison, S., & Gasque, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205023 · Cited by 471
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies
Mueller, A.-L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021) · Cells · doi:10.3390/cells10113017 · Cited by 256
Metadata
- Authors
- Curtis, J. R., & Singh, J. A.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 33
- Issue
- 6
- Pages
- 679-707
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2038593306
- Cited by
- 326
- References
- 83
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.